タイプ2糖尿病：グローバル医薬品市場予測・分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 11
1.1 List of Tables 19
1.2 List of Figures 27
2 Introduction 29
2.1 Catalyst 29
2.2 Related Reports 30
3 Disease Overview 31
3.1 Etiology and Pathophysiology 31
3.1.1 Etiology 31
3.1.2 Pathophysiology 32
3.1.3 Prognosis 33
3.1.4 Quality of Life 34
3.2 Symptoms 34
4 Epidemiology 36
4.1 Risk Factors and Comorbidities 36
4.1.1 Family history of diabetes is a strong predictor of type 2 diabetes 37
4.1.2 The risk of type 2 diabetes increases dramatically around age 50 38
4.1.3 The risk of developing type 2 diabetes increases as BMI increases 39
4.1.4 Gestational diabetes increases the risk of developing type 2 diabetes later in life up to 10 times 40
4.1.5 Up to 75% of adults with type 2 diabetes have hypertension 41
4.1.6 Nearly all type 2 diabetics also have dyslipidemia 42
4.2 Global Trends 43
4.2.1 US 43
4.2.2 5EU 47
4.2.3 Japan 50
4.2.4 Brazil 52
4.2.5 China and India 52
4.3 Forecast Methodology 54
4.3.1 Sources Used 57
4.3.2 Forecast Assumptions and Methods 67
4.3.3 Sources Not Used 76
4.4 Epidemiology Forecast of Type 2 Diabetes (2012-2022) 77
4.4.1 Prevalent Cases of Diagnosed Type 2 Diabetes 77
4.4.2 Age-Specific Prevalent Cases of Diagnosed Type 2 Diabetes 79
4.4.3 Sex-Specific Prevalent Cases of Diagnosed Type 2 Diabetes 81
4.4.4 Age-Standardized Prevalence of Diagnosed Type 2 Diabetes 83
4.4.5 Overweight/Obesity among Diagnosed Prevalent Cases of Type 2 Diabetes 84
4.4.6 Hypertension among Diagnosed Prevalent Cases of Type 2 Diabetes 86
4.4.7 Dyslipidemia among Diagnosed Prevalent Cases of Type 2 Diabetes 88
4.5 Discussion 89
4.5.1 Limitations of the Analysis 92
4.5.2 Strengths of the Analysis 93
5 Disease Management 95
5.1 Treatment Overview 95
5.1.1 Diagnosis and Referrals 95
5.1.2 Treatment Guidelines 96
5.2 US 102
5.2.1 Diagnosis 102
5.2.2 Clinical Practice 102
5.3 France 103
5.3.1 Diagnosis 103
5.3.2 Clinical Practice 103
5.4 Germany 104
5.4.1 Diagnosis 104
5.4.2 Clinical Practice 104
5.5 Italy 106
5.5.1 Diagnosis 106
5.5.2 Clinical Practice 107
5.6 Spain 109
5.6.1 Diagnosis 109
5.6.2 Clinical Practice 109
5.7 UK 110
5.7.1 Diagnosis 110
5.7.2 Clinical Practice 112
5.8 Japan 114
5.8.1 Diagnosis 114
5.8.2 Clinical Practice 114
5.9 China 115
5.9.1 Diagnosis 115
5.9.2 Clinical Practice 116
5.10 India 117
5.10.1 Diagnosis 117
5.10.2 Clinical Practice 117
5.11 Brazil 118
5.11.1 Diagnosis 118
5.11.2 Clinical Practice 118
6 Competitive Assessment 119
6.1 Overview 119
6.2 Strategic Competitor Assessment 120
6.3 Product Profiles – Major Brands 122
6.3.1 Metformin 122
6.3.2 Sulfonylureas (SUs) and Other Insulin Secretagogues 127
6.3.3 α-glucosidase Inhibitors (AGIs) 133
6.3.4 Thiazolidinediones (TZDs) 137
6.3.5 GLP-1 Receptor Agonists 142
6.3.6 DPP-4 Inhibitors 165
6.3.7 SGLT-2 Inhibitors 194
6.3.8 Insulin Formulations 204
7 Opportunity and Unmet Need 231
7.1 Overview 231
7.2 Unmet Needs 232
7.2.1 Drugs Providing Sustained Glycemic Control 232
7.2.2 Drugs with Non-Glycemic Benefits 233
7.2.3 Increased Patient Compliance 234
7.2.4 Drugs with Improved Side-Effect Profiles 235
7.2.5 Earlier Diagnosis 236
7.3 Unmet Needs Gap Analysis 237
7.4 Oral Therapy with Sustainable Efficacy 238
7.5 Oral Therapy Offering Weight Loss 238
7.6 Cardio-metabolic Therapy 239
7.7 Promotion of Type 2 Diabetes Drugs in Emerging Markets 239
8 Pipeline Assessment 240
8.1 Overview 240
8.2 Clinical Trial Mapping 241
8.2.1 Clinical Trials by Country 241
8.3 Clinical Trials by Phase and Trial Status 242
8.4 Promising Drugs in Clinical Development 244
8.4.1 Albiglutide 248
8.4.2 Dulaglutide (LY2189265) 254
8.4.3 Semaglutide 261
8.4.4 Trelagliptin (SYR-472) 266
8.4.5 MK-3102 270
8.4.6 Empagliflozin 275
8.4.7 Tofogliflozin 281
8.4.8 Ipragliflozin 286
8.4.9 LY2409021 291
8.4.10 LY2605541 (insulin peglispro) 296
9 Current and Future Players 302
9.1 Overview 302
9.2 Trends in Corporate Strategy 305
9.3 Company Profiles 306
9.3.1 Eli Lilly 306
9.3.2 Bristol-Myers Squibb 309
9.3.3 Novo Nordisk 313
9.3.4 Sanofi 316
9.3.5 GlaxoSmithKline 318
9.3.6 AstraZeneca 320
9.3.7 Merck & Co 322
9.3.8 Boehringer Ingelheim 324
9.3.9 Takeda 326
9.3.10 Roche 329
9.3.11 Pfizer 330
9.3.12 Johnson & Johnson 332
10 Market Outlook 334
10.1 Global Markets 334
10.1.1 Forecast 334
10.1.2 Drivers and Barriers – Global Issues 339
10.2 US 340
10.2.1 Forecast 340
10.2.2 Key Events 345
10.2.3 Drivers and Barriers 346
10.3 France 348
10.3.1 Forecast 348
10.3.2 Key Events 352
10.3.3 Drivers and Barriers 353
10.4 Germany 355
10.4.1 Forecast 355
10.4.2 Key Events 359
10.4.3 Drivers and Barriers 360
10.5 Italy 361
10.5.1 Forecast 361
10.5.2 Key Events 365
10.5.3 Drivers and Barriers 366
10.6 Spain 367
10.6.1 Forecast 367
10.6.2 Key Events 371
10.6.3 Drivers and Barriers 372
10.7 UK 374
10.7.1 Forecast 374
10.7.2 Key Events 378
10.7.3 Drivers and Barriers 379
10.8 Japan 381
10.8.1 Forecast 381
10.8.2 Key Events 385
10.8.3 Drivers and Barriers 386
10.9 China 388
10.9.1 Forecast 388
10.9.2 Key Events 392
10.9.3 Drivers and Barriers 393
10.10 India 395
10.10.1 Forecast 395
10.10.2 Key Events 399
10.10.3 Drivers and Barriers 399
10.11 Brazil 402
10.11.1 Forecast 402
10.11.2 Key Events 406
10.11.3 Drivers and Barriers 406
11 Appendix 410
11.1 Bibliography 410
11.2 Abbreviations 442
11.3 Methodology 445
11.4 Forecasting Methodology 445
11.4.1 Diagnosed Type 2 Patients 446
11.4.2 Percent Drug-Treated Patients 446
11.4.3 Drugs Included in Each Therapeutic Class 446
11.4.4 Launch and Patent Expiry Dates 447
11.4.5 General Pricing Assumptions 448
11.4.6 Individual Drug Assumptions 449
11.4.7 Generic Erosion 458
11.4.8 Pricing of Pipeline Agents 458
11.5 Physicians and Specialists Included in this Study 460
11.6 About the Authors 462
11.6.1 Analyst II – CVMD 462
11.6.2 Therapy Director – CVMD and Infectious Disease 462
11.6.3 Senior Epidemiologist 463
11.6.4 Global Head of Healthcare 463
11.7 About GlobalData 464
11.8 Disclaimer 464